Pharmacology of Ifosfamide
- 1 November 2003
- journal article
- review article
- Published by S. Karger AG in Oncology
- Vol. 65 (Suppl. 2) , 2-6
- https://doi.org/10.1159/000073350
Abstract
Ifosfamide is a bifunctional alkylating agent, used as a racemic mixture by intravenous route in the treatment of various tumors. It is an oxazaphosphorine derivative with a structural formula similar to that of cyclophosphamide. As a prodrug it requires activation in the liver by a cytochrome mixed-function oxidase system. Among various metabolites, ifosforamide mustard probably represents the most important cytotoxic compound able to produce irreparable cross-links between DNA strands. Resistance is due to the ability of neoplastic cells to repair DNA damages. Acrolein may induce hemorrhagic cystitis, whereas chloroacetaldehyde may be responsible both for nephro- and neurotoxicity. A thiol donor (mesna) can prevent urotoxic effects but not nephro- and neurotoxicity. Pharmacokinetics is markedly influenced by route of administration and duration of treatment, age, co-medication, liver and renal function.Keywords
This publication has 12 references indexed in Scilit:
- Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamideZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomasAnnals of Oncology, 2002
- Modulation of the cytochrome P450–mediated metabolism of ifosfamide by ketoconazole and rifampinClinical Pharmacology & Therapeutics, 2001
- Distribution of ifosfamide and metabolites between plasma and erythrocytesBiopharmaceutics & Drug Disposition, 2001
- Pharmacokinetics of Ifosfamide Are Changed by Combination With DocetaxelAmerican Journal of Clinical Oncology, 2000
- Increased urinary losses of carnitine during ifosfamide chemotherapyCancer Chemotherapy and Pharmacology, 1999
- Activated oxazaphosphorines are transported predominantly by erythrocytesAnnals of Oncology, 1997
- A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cyclesPublished by Wiley ,1996
- De Novo Expression of Transfected Human Class 1 Aldehyde Dehydrogenase (ALDH) Causes Resistance to Oxazaphosphorine Anti-cancer Alkylating Agents in Hamster V79 Cell LinesPublished by Elsevier ,1996
- Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cellsBiochemical Pharmacology, 1984